Key facts
as of Sep 2026- Illuminare Biotechnologies’s last known valuation is $11.4M (Aug 2017).
- It has raised $7.1M across 1 recorded rounds; the latest was Seed Round ($3.6M) in May 2026.
- Notable investors include Memorial Sloan Kettering Cancer Center, Endo Investors, GE Aerospace, Thylacine Capital.
- 1 institutional filer reports fund marks on Illuminare Biotechnologies across 2 filings.
- Illuminare Biotechnologies has filed 1 Form D with the SEC, most recently Dec 2018 ( sold).
- Status: Privately Held (backing).
PA Mark — composite indicative price
LOW confidence~$123per share
as of Sep 2026 · the exact daily mark is a member feature
Free account
See the evidence behind this price
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Illuminare Biotechnologies
Create free account
No card required
Recorded secondary trades
No prints on record
No secondary trades in Illuminare Biotechnologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
1 filers · latest Mar 20261 SEC-registered fund reported 2 fair-value marks on Illuminare Biotechnologies between Dec 2025 and Mar 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
1 roundsAbout Illuminare Biotechnologies
Developer of an intra-operative nerve visualization technology intended to reduce the risk of nerve damage. The company's technology binds specifically to myelin and illuminates to make nerves, fat, muscles, and blood vessels more visible, enabling surgeons with improved visibility during operations.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2016
- Website
- illuminarebio.com/
- Ownership
- Privately Held (backing)